Eli Lilly and Company (NYSE: LLY) will begin rollout of its first connected platform, the Tempo® Personalized Diabetes Management Platform, later this year in the U.S. The technology aims to help adults living with type 1 or type 2 diabetes and clinicians make informed, data-backed decisions to manage treatment .
Centralized experience supports diabetes self-management through medication reminders, education resources and insulin dose loggingData shared through platform interface may help healthcare.